RemeGen Co. Ltd. Class H (HK:9995)
:9995
Want to see HK:9995 full AI Analyst Report?
9995 Stock Chart & Stats
HK$119.90
-HK$0.38(-3.04%)
At close: 4:00 PM EST
HK$119.90
-HK$0.38(-3.04%)
Day’s Range― - ―
52-Week RangeHK$47.30 - HK$126.60
Previous CloseN/A
Volume1.38M
Average Volume (3M)6.34M
Market Cap
HK$57.04B
Enterprise ValueHK$65.18B
Total Cash (Recent Filing)HK$2.74B
Total Debt (Recent Filing)HK$2.09B
Price to Earnings (P/E)45.1
Beta1.51
Next Earnings
Aug 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.29
Shares Outstanding208,581,240
10 Day Avg. Volume6,644,676
30 Day Avg. Volume6,343,592
Financial Highlights & Ratios
PEG Ratio-0.34
Price to Book (P/B)9.84
Price to Sales (P/S)11.22
P/FCF Ratio-253.57
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$129.32Price Target Upside7.86% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)5.66
Revenue Forecast (FY)HK$7.08B
Bulls Say, Bears Say
Bulls Say
Profitability TurnaroundThe company has moved from multi-year losses to sustained positive operating and net margins (~21.8%). Durable high margins signal pricing power or favorable cost structure, enabling internal funding for R&D and commercialization and improving long-term self-sufficiency if maintained.
Strong Revenue GrowthSharp TTM revenue acceleration demonstrates real demand and commercial traction for products or late-stage programs. Durable top-line growth supports economies of scale, funds continued pipeline investment, and underpins a structural shift from development-stage losses to operating leverage over the medium term.
Improved Capital EfficiencyLower leverage versus the prior year and a strong trailing ROE (~28%) indicate improving capital efficiency and balance-sheet repair. A healthier mix of equity and debt increases financial flexibility for business investment and partnerships, reducing structural default risk if trends persist.
Bears Say
Weak Cash ConversionReported profits are not translating into cash: OCF/NI ~0.02 and only modest positive free cash flow in TTM after prior negative years. This undermines durability of earnings, constrains reinvestment or debt repayment capacity, and raises dependence on external financing over the medium term.
Earnings VolatilityLarge multi-year swings between heavy losses and recent profitability reduce predictability of future results. Such volatility complicates long-term planning, makes benchmarking and guidance less reliable, and increases execution risk for commercialization and pipeline funding decisions over 2–6 months.
Elevated Leverage Vs Historical Conservative LevelsAlthough leverage has improved from 2024 highs, it remains elevated versus the company's earlier conservative profile. Combined with weak cash conversion, this increases refinancing and covenant risk and limits strategic optionality for M&A or stepped-up commercial investment during downturns.
RemeGen Co. Ltd. Class H News
9995 FAQ
What was RemeGen Co. Ltd. Class H’s price range in the past 12 months?
RemeGen Co. Ltd. Class H lowest stock price was HK$47.30 and its highest was HK$126.60 in the past 12 months.
What is RemeGen Co. Ltd. Class H’s market cap?
RemeGen Co. Ltd. Class H’s market cap is HK$57.04B.
When is RemeGen Co. Ltd. Class H’s upcoming earnings report date?
RemeGen Co. Ltd. Class H’s upcoming earnings report date is Aug 26, 2026 which is in 76 days.
How were RemeGen Co. Ltd. Class H’s earnings last quarter?
RemeGen Co. Ltd. Class H released its earnings results on Apr 28, 2026. The company reported HK$0.665 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.665.
Is RemeGen Co. Ltd. Class H overvalued?
According to Wall Street analysts RemeGen Co. Ltd. Class H’s price is currently Undervalued.
Does RemeGen Co. Ltd. Class H pay dividends?
RemeGen Co. Ltd. Class H does not currently pay dividends.
What is RemeGen Co. Ltd. Class H’s EPS estimate?
RemeGen Co. Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does RemeGen Co. Ltd. Class H have?
RemeGen Co. Ltd. Class H has 208,581,240 shares outstanding.
What happened to RemeGen Co. Ltd. Class H’s price movement after its last earnings report?
RemeGen Co. Ltd. Class H reported an EPS of HK$0.665 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -0.476%.
Which hedge fund is a major shareholder of RemeGen Co. Ltd. Class H?
Currently, no hedge funds are holding shares in HK:9995
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
RemeGen Co. Ltd. Class H Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
HK$129.32 (7.86% Upside)
HK$129.32 (7.86% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
495.23%
12-Months-Change
Fundamentals
Return on Equity
42.27%
Trailing 12-Months
Asset Growth
46.80%
Trailing 12-Months
Company Description
RemeGen Co. Ltd. Class H
RemeGen Co., Ltd. is a biopharmaceutical firm dedicated to the innovation, advancement, and marketing of biologic therapies. The company targets critical unmet medical requirements in autoimmune, oncological, and ophthalmic diseases within Mainland China and the United States. Its current offerings include Telitacicept (RC18), prescribed for the autoimmune condition systemic lupus erythematosus, and Disitamab Vedotin (RC48), utilized in treating various types of cancer. RemeGen maintains a comprehensive pipeline of product candidates at different development phases. RC18 is progressing through Phase III clinical trials for neuromyelitis optica spectrum disorder and rheumatoid arthritis, and Phase II trials for IgA nephritis, Sjögren's syndrome, multiple sclerosis, and myasthenia gravis. RC28 has concluded Phase 1 clinical studies for wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. In oncology, RC98, a PD-L1 monoclonal antibody, is undergoing Phase I clinical trials for solid tumors. Additionally, RC88 is in Phase 1 trials for mesothelioma, bile duct carcinoma, pancreatic cancer, ovarian carcinoma, lung adenocarcinoma, other solid tumors, as well as lung and urothelial cancer, while RC108 is in Phase 1 trials for various solid tumors. Furthermore, several products are in pre-clinical development, including RC118, RC138, RC148, RC158, RC168, RC178, RC188, and RC198, all designed for diverse solid tumors. Ophthalmic disease treatments under pre-clinical investigation include RC208, RC218, and RC228. Founded in 2008, RemeGen Co., Ltd. is headquartered in Yantai, People's Republic of China.
9995 Stock 12 Month Forecast
Average Price Target
HK$129.32
▲(7.86% Upside)
Technical Analysis
Akeso, Inc.
―
Alphamab Oncology
―
InnoCare Pharma Ltd.
―
Shanghai Junshi Biosciences Co., Ltd. Class H
―
Shanghai Henlius Biotech, Inc. Class H
―
Options Prices
Currently, No data available
---